
FDA clears Motivista, a prescription smartphone digital therapeutic, to reduce negative symptoms of schizophrenia—supported by phase 3 results and strong patient engagement.
Two Portraits of AIDS - Poetry of the Times
© CME LLC
11/97
almost 29 years ago
Commentary: A Victory for Patientsalmost 29 years ago
Commentary: Ablow Shruggedalmost 29 years ago
Mysterious Brain Disease Defies Easy Solutionalmost 29 years ago
Consumer Employment: Advocacy Assumes Another Facealmost 29 years ago
The S.O.S. Campaign: Educating the Public About Schizophreniaalmost 29 years ago
Trichotillomania: Out of the Closetalmost 29 years ago
Trichotillomania: Out of the Closetalmost 29 years ago
New Weight Loss Controversy Flaresalmost 29 years ago
Late-Life Depression, Dementias- Top Educational Priorities for AAGP





